Daniel V. LaBarbera

2.5k total citations · 1 hit paper
54 papers, 1.9k citations indexed

About

Daniel V. LaBarbera is a scholar working on Molecular Biology, Oncology and Biotechnology. According to data from OpenAlex, Daniel V. LaBarbera has authored 54 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 16 papers in Oncology and 9 papers in Biotechnology. Recurrent topics in Daniel V. LaBarbera's work include Aldose Reductase and Taurine (8 papers), Cancer Cells and Metastasis (8 papers) and Cancer therapeutics and mechanisms (7 papers). Daniel V. LaBarbera is often cited by papers focused on Aldose Reductase and Taurine (8 papers), Cancer Cells and Metastasis (8 papers) and Cancer therapeutics and mechanisms (7 papers). Daniel V. LaBarbera collaborates with scholars based in United States, Hungary and Brazil. Daniel V. LaBarbera's co-authors include J. Mark Petrash, Byong Hoon Yoo, Brian G. Reid, Qiong Zhou, David G. Holm, Sastry S. Jayanty, Linfeng Li, Diganta Kalita, Jessica Ponder and Kun‐Che Chang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and PLoS ONE.

In The Last Decade

Daniel V. LaBarbera

53 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers

2018 374 citations Nikita Pozdeyev, Laurie M. Gay et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel V. LaBarbera United States	24	726	521	475	293	201	54	1.9k
Hui Jing China	34	1.4k 1.9×	443 0.9×	84 0.2×	235 0.8×	161 0.8×	95	3.1k
Sankar Mohan Canada	23	842 1.2×	360 0.7×	310 0.7×	69 0.2×	48 0.2×	43	1.9k
Christopher R. Ireson United Kingdom	14	1.7k 2.3×	333 0.6×	154 0.3×	165 0.6×	65 0.3×	18	3.0k
Chih‐Pin Chuu Taiwan	32	1.5k 2.1×	511 1.0×	179 0.4×	68 0.2×	181 0.9×	100	2.8k
Adam Yasgar United States	25	1.4k 1.9×	286 0.5×	68 0.1×	144 0.5×	112 0.6×	51	2.4k
Yanna Cheng China	29	933 1.3×	266 0.5×	79 0.2×	104 0.4×	122 0.6×	66	2.0k
J. Vázquez France	7	1.2k 1.6×	615 1.2×	86 0.2×	85 0.3×	130 0.6×	13	2.2k
Tsuneo Imanaka Japan	36	3.0k 4.2×	440 0.8×	200 0.4×	67 0.2×	331 1.6×	160	4.5k
Sangtaek Oh South Korea	34	2.7k 3.7×	730 1.4×	87 0.2×	97 0.3×	224 1.1×	93	4.0k
Dipak Datta India	30	1.1k 1.6×	691 1.3×	53 0.1×	125 0.4×	122 0.6×	84	2.5k

Countries citing papers authored by Daniel V. LaBarbera

Since Specialization

Citations

This map shows the geographic impact of Daniel V. LaBarbera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel V. LaBarbera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel V. LaBarbera more than expected).

Fields of papers citing papers by Daniel V. LaBarbera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel V. LaBarbera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel V. LaBarbera. The network helps show where Daniel V. LaBarbera may publish in the future.

Co-authorship network of co-authors of Daniel V. LaBarbera

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel V. LaBarbera. A scholar is included among the top collaborators of Daniel V. LaBarbera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel V. LaBarbera. Daniel V. LaBarbera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sala, Rita, et al.. (2024). CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos. International Journal of Molecular Sciences. 25(16). 8590–8590. 3 indexed citations

Sala, Rita, Hector Esquer, Paul Awolade, et al.. (2024). CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models. International Journal of Molecular Sciences. 25(23). 13160–13160. 1 indexed citations

Awolade, Paul, Qiong Zhou, Hector Esquer, et al.. (2023). The validation of new CHD1L inhibitors as a therapeutic strategy for cancer. Biomedicine & Pharmacotherapy. 170. 116037–116037. 2 indexed citations

Prigaro, Brett J., Hector Esquer, Qiong Zhou, et al.. (2022). Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. Journal of Medicinal Chemistry. 65(5). 3943–3961. 11 indexed citations

Marentette, John, Hector Esquer, Daniel V. LaBarbera, et al.. (2022). Oxidative stress as a candidate mechanism for accelerated neuroectodermal differentiation due to trisomy 21. Free Radical Biology and Medicine. 186. 32–42. 7 indexed citations

Zhou, Qiong, Hector Esquer, Laura A. Pike, et al.. (2020). First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Molecular Cancer Therapeutics. 19(8). 1598–1612. 23 indexed citations

Esquer, Hector, et al.. (2020). Advanced High-Content-Screening Applications of Clonogenicity in Cancer. SLAS DISCOVERY. 25(7). 734–743. 16 indexed citations

Schweppe, Rebecca E., Nikita Pozdeyev, Laura A. Pike, et al.. (2019). Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Molecular Cancer Research. 17(5). 1036–1048. 12 indexed citations

Pozdeyev, Nikita, Laurie M. Gay, Ethan Sokol, et al.. (2018). Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clinical Cancer Research. 24(13). 3059–3068. 374 indexed citations breakdown →

10.

Li, Linfeng, et al.. (2018). Identification of small molecule inhibitors of the Chikungunya virus nsP1 RNA capping enzyme. Antiviral Research. 154. 124–131. 42 indexed citations

11.

Hoffman, Ann F., Kaylene J. Simpson, Péter Horváth, et al.. (2017). SBI ² HCS/HCA 3D Imaging: Best Practices and Unmet Needs Colloquium. Assay and Drug Development Technologies. 15(1). 1–7. 2 indexed citations

12.

Bashyal, Bharat P., et al.. (2017). Larrea tridentata: A novel source for anti-parasitic agents active against Entamoeba histolytica, Giardia lamblia and Naegleria fowleri. PLoS neglected tropical diseases. 11(8). e0005832–e0005832. 29 indexed citations

13.

McGinn, Olivia, et al.. (2017). Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells. Oncogene. 36(44). 6074–6084. 24 indexed citations

14.

LaBarbera, Daniel V., et al.. (2014). The Characterization and Therapeutic Development of Natural Products from E. Officinalis: An Ayurvedic Medicinal Plant Used to Treat Diabetic Eye Disease. The Journal of Alternative and Complementary Medicine. 20(5). A26–A26. 1 indexed citations

15.

LaBarbera, Daniel V., Brian G. Reid, & Byong Hoon Yoo. (2012). The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opinion on Drug Discovery. 7(9). 819–830. 200 indexed citations

16.

Chang, Kun‐Che, Brian Laffin, Jessica Ponder, et al.. (2012). Beta-glucogallin reduces the expression of lipopolysaccharide-induced inflammatory markers by inhibition of aldose reductase in murine macrophages and ocular tissues. Chemico-Biological Interactions. 202(1-3). 283–287. 45 indexed citations

17.

Muthenna, Puppala, Jessica Ponder, Palla Suryanarayana, et al.. (2012). The Isolation and Characterization of β-Glucogallin as a Novel Aldose Reductase Inhibitor from Emblica officinalis. PLoS ONE. 7(4). e31399–e31399. 89 indexed citations

18.

Laird, Damian W., et al.. (2007). Halogenated cyclic peptides isolated from the sponge Corticium sp.. Murdoch Research Repository (Murdoch University). 1 indexed citations

19.

Lira, Simone Possedente de, Mirna Helena Regali Seleghim, Tim S. Bugni, et al.. (2006). New Destruxins from the Marine-derived Fungus Beauveria felina. The Journal of Antibiotics. 59(9). 553–563. 38 indexed citations

20.

LaBarbera, Daniel V. & Edward B. Skibo. (2004). Synthesis of imidazo[1,5,4-de]quinoxalin-9-ones, benzimidazole analogues of pyrroloiminoquinone marine natural products. Bioorganic & Medicinal Chemistry. 13(2). 387–395. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact